

Wei Qin Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4102522/publications.pdf>

Version: 2024-02-01

8
papers

563
citations

1307594

7
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

872
citing authors

#	ARTICLE	IF	CITATIONS
1	Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. <i>Cancer Letters</i> , 2022, 525, 115-130.	7.2	19
2	Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. , 2022, 19, 834-847.		33
3	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	59
4	Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 365-379.	12.1	117
5	ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy. <i>Nature Communications</i> , 2019, 10, 3391.	12.8	75
6	Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. <i>Nucleic Acids Research</i> , 2018, 46, 8832-8847.	14.5	40
7	Epigenetic Silencing of miR-490-3p Reactivates the Chromatin Remodeler SMARCD1 to Promote <i>Helicobacter pylori</i> -Induced Gastric Carcinogenesis. <i>Cancer Research</i> , 2015, 75, 754-765.	0.9	115
8	Histone Deacetylase HDAC8 Promotes Insulin Resistance and β -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015, 75, 4803-4816.	0.9	105